In the ebb and flow of the Biotech and Pharma sectors, workforce adjustments reflect not only individual corporate strategies but also broader industry trends. October 2023 has been a poignant month for the sector as various companies recalibrated their operations amidst challenging market dynamics. This Layoff Tracker serves as a vital instrument, chronicling the difficult decisions made by organizations striving to navigate an increasingly complex healthcare landscape. It offers a meticulous record of job reductions, aiming to provide stakeholders with transparent insights into the evolving fabric of the industry. As we delve into the data, we bear witness to the resilience of the sector and its workforce, even in the face of formidable headwinds.
| Date | Company Name | Number of Layoffs | Reason for Layoff |
| Oct. 30 | Galapagos | Approximately 100 | Transfer of Jyseleca (filgotinib) to Alfasigma |
| Oct. 30 | Pfizer | Unspecified | Facility closure and reassignment |
| Oct. 26 | ElevateBio | 13% | Workforce reduction despite recent financing |
| Oct. 24 | Amgen | 350 | After acquisition of Horizon Therapeutics |
| Oct. 24 | BrainStorm Cell Therapeutics | 30% of staff | Strategic realignment following FDA decision |
| Oct. 24 | Idorsia Pharmaceuticals | Approximately 475 | Sales of insomnia drug and cost-saving measures |
| Oct. 19 | Beam Therapeutics | Approximately 100 | Restructuring to fund company into 2026 |
| Oct. 16 | Nkarta | 18 | Focus on later-stage programs and cost containment |
| Oct. 13 | Pfizer | Layoffs announced, number unclear | Cost-cutting initiative due to declining COVID-19 product sales |
| Oct. 11 | Sana Biotechnology | 29% of workforce | Portfolio realignment and cash conservation |
| Oct. 9 | Biogen (Reata Pharmaceuticals) | 113 | After acquisition and cost-reduction program |
| Oct. 7 | Eikon Therapeutics | Unspecified | Efforts to become more efficient and streamline |
| Oct. 5 | Atsena Therapeutics | Unspecified | Layoffs for cash conservation and focus on trials |
| Oct. 5 | uniQure | 114 | Restructuring to focus on specific programs and cost savings |
| Oct. 3 | Kezar Life Sciences | 41% of workforce | Focus on clinical trials and securing funds |
| Oct. 2 | Syros Pharmaceuticals | 35% of workforce | Focus on specific clinical trials and leadership changes |
Also Read: September Layoffs
As we conclude this monthly odyssey, our Layoff Tracker has encapsulated the bittersweet narrative of transition within the Biotech and Pharma sectors. The job cuts reported in October 2023 are not merely statistics; they symbolize the lives and communities undergoing realignment.
Don’t miss out on our upcoming tracker update. We will be posting it every month. To get notified as soon as it’s ready, subscribe to our website’s notification system now.
